Which Blood Tests Should Continue for Life — And Who Actually Orders Them

Which Blood Tests Should Continue for Life After Immunotherapy?

For most people the lifelong list is short: thyroid function, and cortisol where the pituitary or adrenal gland was affected. Everything else is reviewed and usually tapers. Those two watch a gland rather than the cancer, and a gland that stopped working during treatment often does not restart on its own.

This is the part of survivorship that quietly falls off. Cancer surveillance has a shape everyone recognises: scans, intervals, a discharge date. Endocrine monitoring has no such shape, so it ends by accident. The appointments thin out, the requisition slip stops being written, and a test that was meant to run for life stops in year two because nobody said out loud that it was different from the others.

What continues, and what tapers

Source: this pattern follows the way NCCN, ASCO and ESMO describe monitoring for immune-related adverse events after checkpoint inhibitor treatment. It is a general shape, not a prescription. Nobody has every row on their list, and which rows are on yours is a clinical decision made by your oncologist and, where a gland is involved, your endocrinologist.

Which Hormones Need Monitoring After Immunotherapy?

Thyroid first, cortisol second. Thyroid dysfunction is the commonest lasting endocrine effect of checkpoint inhibitors, and it is frequently silent. Pituitary or adrenal inflammation is less common but carries more risk, because low cortisol can present as collapse during an ordinary infection. Blood sugar is monitored where immunotherapy-related diabetes has appeared.

Each of these behaves differently, and it helps to know which one you are being followed for. A thyroid problem is usually managed with a tablet and an occasional dose adjustment. An adrenal problem changes what you do when you fall ill, and comes with a steroid card and written sick-day instructions from an endocrinologist. Immunotherapy-related diabetes is uncommon, can begin abruptly, and is generally permanent once it has started.

The hormone lines that are followed, and what happens if one is abnormal

Which of these lines is followed in your case, and for how long, is clinician-directed. Nothing here predicts what will happen to you, and none of it is a prognosis. If you are already living with replacement therapy, living with lifelong hormone replacement covers the day-to-day side of it.

How Often Should These Tests Be Repeated?

Every review in year one, then progressively further apart. Most people have bloods at each visit for the first twelve months, commonly every one to three months. In years two and three the gap usually widens to three to six months. A hormone on stable replacement is often checked every six to twelve months, and sooner after any dose change.

• Year one is the dense part. Immune effects can still appear or worsen after the last dose, so bloods generally accompany every review in this period.
• Years two and three widen out. As cancer surveillance eases, the blood panel usually shortens too — except for the hormone tests, which do not.
• Stable replacement has its own rhythm. Once a levothyroxine or steroid dose is settled, six to twelve monthly is a common pattern, set by whoever manages the replacement.
• Any dose change resets the clock. A recheck roughly six to eight weeks after a change is the usual practice, because that is how long a new level takes to show.
• Symptoms override the calendar. A test is done when something changes, not only when a date arrives. That applies for life, not only during follow-up.

These intervals describe the general pattern in NCCN, ASCO and ESMO guidance on immune-related adverse events. Long-term data on checkpoint inhibitors is still emerging, so nobody can yet say with precision how far into the future these tests remain useful. Your own intervals are set by your treating team. The full visit-by-visit picture sits in your follow-up schedule after immunotherapy.

Who Orders These Blood Tests Once Follow-Up Ends?

Your oncologist while you are in cancer follow-up, your endocrinologist for anything on replacement, and your physician or family doctor after discharge. The failure that actually happens is not a wrong test. It is three clinicians each assuming one of the others is ordering it, and the tests stopping.

Handover is where lifelong monitoring is won or lost. Nobody refuses to order a thyroid test. It simply never gets requested, because the oncology file has closed, the endocrinology appointment was a year ago, and the family doctor was never told that this particular patient needs a TSH every year for the rest of their life.

• Your oncologist. Orders the surveillance panel during follow-up and decides when the cancer-facing tests can taper.
• Your endocrinologist. Takes over any hormone that needs replacement, sets its own interval and writes the sick-day rules that go with steroids.
• Your physician or family doctor. Holds the repeats after discharge. They can only do that if someone tells them what is needed and how often.
• You. The one person present at every appointment. Keep a one-page summary: diagnosis, drug name, number of cycles, date of last dose, which glands were affected, current doses, and the tests that are meant to continue.
• Ask for it in writing. A list with intervals and a named owner for each test is worth more than any verbal reassurance a year later.

This is precisely what a written survivorship plan is for — see your survivorship care plan after immunotherapy. At CION, immunotherapy is given as a day-care infusion and the same medical oncology team handles review afterwards; response-assessment imaging such as PET-CT is coordinated at partner imaging centres rather than owned by us.

What Happens If Thyroid and Cortisol Monitoring Stops?

Both problems are silent until they are not. An underactive thyroid arrives as tiredness, weight gain, cold intolerance and low mood, all of which get blamed on recovery. Low cortisol is the more dangerous of the two: it can stay quiet for months and then declare itself as an adrenal crisis during an ordinary infection.

• Do not stop replacement on your own. Feeling well on levothyroxine or hydrocortisone is the treatment working, not a sign it is no longer needed.
• Carry a steroid card. The people who most need to read it are people you have never met, in a department you did not plan to visit.
• Tell every doctor, forever. Dentists, surgeons and physicians in another city. The drug name and the date of your last dose belong in your first sentence.
• Book bloods before surgery or a long trip. Illness, an operation and sometimes travel are the moments a borderline cortisol becomes a problem.
• Treat new symptoms on their own merits. Immune effects can begin months after the final dose, so “I finished treatment ages ago” is not a reason to wait.

Long-term evidence here is still emerging. Modern checkpoint inhibitors have only been in wide clinical use since the mid-2010s, so how these effects behave over decades is not yet known with confidence. Continued monitoring is the response to that uncertainty, not a prediction about your outcome.

Where Survivorship Questions Usually Go Next

A test list answers what and how often. The questions that follow it are broader: how much of ordinary life comes back, what family planning looks like afterwards, and how the whole plan gets written down in one place. Each has its own page below, and the general picture of the treatment itself starts at immunotherapy at CION Cancer Clinics.

The Tests That Should Not Have Stopped

A survivorship review can put thyroid and cortisol monitoring back on a schedule — in writing, with the intervals on it.